Impact of Epstein-Barr virus and CD lymphocytes on the prognosis of patients with advanced nasopharyngeal carcinoma.

IF 3.1 2区医学 Q3 IMMUNOLOGY

Infectious Agents and Cancer Pub Date : 2025-02-19 DOI:10.1186/s13027-025-00638-2

Fangchu Liu, Yonghua Peng, Xintao Wang, Weili Long, Zhenhe Huang

{"title":"Impact of Epstein-Barr virus and CD lymphocytes on the prognosis of patients with advanced nasopharyngeal carcinoma.","authors":"Fangchu Liu, Yonghua Peng, Xintao Wang, Weili Long, Zhenhe Huang","doi":"10.1186/s13027-025-00638-2","DOIUrl":null,"url":null,"abstract":"Background: Understanding the factors influencing the occurrence and progression of nasopharyngeal carcinoma (NPC) is critical for reducing incidence rates and improving patient outcomes. The objective of this study is to preliminarily investigate the impact of Epstein-Barr virus (EBV) and cluster of differentiation (CD) lymphocytes on the prognosis of patients with advanced NPC.Method: A prospective cohort study design was employed, involving newly diagnosed patients with NPC confirmed by pathological diagnosis. Patients received standard radiotherapy and chemotherapy according to treatment guidelines, with regular follow-up assessments conducted. Prior to treatment initiation, patients underwent testing for EBV, blood biochemistry, and other parameters, while baseline data including patient age, pathology, and tumor node metastasis classification (TNM) staging were also collected. The primary outcome measure focused on disease progression.Results: The analysis included a total of 99 cases, with a median age of 52 years, all of whom were stage III or IV patients. The median progression-free survival time for the patients was 45.53 months. After adjusting for confounding factors such as age, T stage, and metastasis, patients with low levels of B cells exhibited a 1.503-fold increased risk of progression compared to those with high levels of B cells (adjusted hazard ratio [HR] = 2.503; 95% confidence interval [CI]: 1.062-5.899). Patients infected with EBV had a 1.739-fold increased risk of progression compared to uninfected patients (adjusted HR = 2.739; 95% CI: 1.222-6.125).Conclusion: This study observed that patients with advanced nasopharyngeal carcinoma, infected with EBV and exhibiting diminished B cell levels, display heightened susceptibility to disease deterioration and progression.","PeriodicalId":13568,"journal":{"name":"Infectious Agents and Cancer","volume":"20 1","pages":"10"},"PeriodicalIF":3.1000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11840979/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Agents and Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13027-025-00638-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Understanding the factors influencing the occurrence and progression of nasopharyngeal carcinoma (NPC) is critical for reducing incidence rates and improving patient outcomes. The objective of this study is to preliminarily investigate the impact of Epstein-Barr virus (EBV) and cluster of differentiation (CD) lymphocytes on the prognosis of patients with advanced NPC.

Method: A prospective cohort study design was employed, involving newly diagnosed patients with NPC confirmed by pathological diagnosis. Patients received standard radiotherapy and chemotherapy according to treatment guidelines, with regular follow-up assessments conducted. Prior to treatment initiation, patients underwent testing for EBV, blood biochemistry, and other parameters, while baseline data including patient age, pathology, and tumor node metastasis classification (TNM) staging were also collected. The primary outcome measure focused on disease progression.

Results: The analysis included a total of 99 cases, with a median age of 52 years, all of whom were stage III or IV patients. The median progression-free survival time for the patients was 45.53 months. After adjusting for confounding factors such as age, T stage, and metastasis, patients with low levels of B cells exhibited a 1.503-fold increased risk of progression compared to those with high levels of B cells (adjusted hazard ratio [HR] = 2.503; 95% confidence interval [CI]: 1.062-5.899). Patients infected with EBV had a 1.739-fold increased risk of progression compared to uninfected patients (adjusted HR = 2.739; 95% CI: 1.222-6.125).

Conclusion: This study observed that patients with advanced nasopharyngeal carcinoma, infected with EBV and exhibiting diminished B cell levels, display heightened susceptibility to disease deterioration and progression.

查看原文本刊更多论文

eb病毒和CD淋巴细胞对晚期鼻咽癌患者预后的影响。

背景：了解鼻咽癌（NPC）发生发展的影响因素对降低鼻咽癌发病率和改善患者预后至关重要。本研究旨在初步探讨eb病毒（EBV）和分化聚集性淋巴细胞（CD）对晚期鼻咽癌患者预后的影响。方法：采用前瞻性队列研究设计，纳入病理确诊的新诊断鼻咽癌患者。患者根据治疗指南接受标准放疗和化疗，并定期随访评估。在治疗开始前，患者接受EBV、血液生化和其他参数的检测，同时收集患者年龄、病理和肿瘤淋巴结转移分期等基线数据。主要结局指标侧重于疾病进展。结果：分析共纳入99例，中位年龄52岁，均为III期或IV期患者。患者的中位无进展生存期为45.53个月。在校正了年龄、T分期和转移等混杂因素后，B细胞水平低的患者与B细胞水平高的患者相比，进展的风险增加了1.503倍(校正风险比[HR] = 2.503；95%置信区间[CI]: 1.062-5.899)。与未感染的患者相比，感染EBV的患者进展风险增加了1.739倍(调整后的HR = 2.739；95% ci: 1.222-6.125)。结论：本研究观察到晚期鼻咽癌患者感染eb病毒并表现出B细胞水平降低，对疾病恶化和进展的易感性增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious Agents and Cancer ONCOLOGY-IMMUNOLOGY

CiteScore

5.80

自引率

2.70%

发文量

期刊介绍： Infectious Agents and Cancer is an open access, peer-reviewed online journal that encompasses all aspects of basic, clinical, epidemiological and translational research providing an insight into the association between chronic infections and cancer. The journal welcomes submissions in the pathogen-related cancer areas and other related topics, in particular: • HPV and anogenital cancers, as well as head and neck cancers; • EBV and Burkitt lymphoma; • HCV/HBV and hepatocellular carcinoma as well as lymphoproliferative diseases; • HHV8 and Kaposi sarcoma; • HTLV and leukemia; • Cancers in Low- and Middle-income countries. The link between infection and cancer has become well established over the past 50 years, and infection-associated cancer contribute up to 16% of cancers in developed countries and 33% in less developed countries. Preventive vaccines have been developed for only two cancer-causing viruses, highlighting both the opportunity to prevent infection-associated cancers by vaccination and the gaps that remain before vaccines can be developed for other cancer-causing agents. These gaps are due to incomplete understanding of the basic biology, natural history, epidemiology of many of the pathogens that cause cancer, the mechanisms they exploit to cause cancer, and how to interrupt progression to cancer in human populations. Early diagnosis or identification of lesions at high risk of progression represent the current most critical research area of the field supported by recent advances in genomics and proteomics technologies.